Dr. Robert W. Naumann, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 122
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
NC license 9601138 -
Obstetrics & Gynecology Physician
NC license 9601138
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carolinas Medical Center/behav Health Charlotte, NC
- Atrium Health Pineville Charlotte, NC
- Atrium Health Union Monroe, NC
- Atrium Health Cleveland Shelby, NC
- Caromont Regional Medical Center Gastonia, NC
Medical groups
- Carolinas Medical Center (1,067 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 122
- Services billed
- 905
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 174 | 37 |
| Established patient office or other outpatient visit, 20-29 minutes | 74 | 64 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 57 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Charlotte, NC | 30 |
| Lynparza (olaparib) | 28 |
| Letrozole Other prescribers in Charlotte, NC | 27 |
| Levothyroxine Sodium Other prescribers in Charlotte, NC | 22 |
| Prochlorperazine Maleate Other prescribers in Charlotte, NC | 20 |
| Megestrol Acetate Other prescribers in Charlotte, NC | 19 |
| Dexamethasone Other prescribers in Charlotte, NC | 15 |
| Tamoxifen Citrate Other prescribers in Charlotte, NC | 14 |
| Xarelto (rivaroxaban) Other prescribers in Charlotte, NC | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 25 payments worth $15,431 in total to this clinician.
| Eisai Inc. | $4,096 |
|---|---|
| AbbVie Inc. | $3,057 |
| Medical Device Business Services, Inc. | $2,551 |
| GlaxoSmithKline, LLC. | $2,481 |
| Ethicon US, LLC | $2,196 |
| Genmab U.S., Inc. | $800 |
| Caris Mpi, Inc. | $130 |
| AstraZeneca Pharmaceuticals LP | $71.18 |
| Consulting Fee | $11,480 |
|---|---|
| Travel and Lodging | $3,137 |
| Food and Beverage | $788 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Apr 23, 2025 | Consulting Fee Lenvima · Oncology | $4,075 |
| AbbVie Inc. Jul 7, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,175 |
| Ethicon US, LLC Oct 9, 2025 | Consulting Fee SURGICEL NU-KNIT · Biosurgical | $2,030 |
| GlaxoSmithKline, LLC. May 7, 2025 | Consulting Fee | $2,000 |
| Medical Device Business Services, Inc. Sep 15, 2025 | Travel and Lodging Harmonic · Energy · travel to RIDGELAND, MS · in-kind | $1,387 |
| Genmab U.S., Inc. Aug 1, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $800 |
| Medical Device Business Services, Inc. Sep 15, 2025 | Travel and Lodging Harmonic · Energy · travel to RIDGELAND, MS · in-kind | $777 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee | $400 |
| AbbVie Inc. May 30, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $392 |
| AbbVie Inc. May 31, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $293 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Ethicon US, LLC Oct 9, 2025 | Consulting Fee SURGICEL NU-KNIT · Biosurgical | $2,030 |
| Ethicon US, LLC Oct 9, 2025 | Travel and Lodging SURGICEL NU-KNIT · Biosurgical · travel to CHARLOTTE, NC | $49.84 |
| Medical Device Business Services, Inc. Sep 15, 2025 | Travel and Lodging Harmonic · Energy · travel to RIDGELAND, MS · in-kind | $1,387 |
| Medical Device Business Services, Inc. Sep 15, 2025 | Travel and Lodging Harmonic · Energy · travel to RIDGELAND, MS · in-kind | $777 |
| Medical Device Business Services, Inc. Sep 15, 2025 | Travel and Lodging Harmonic · Energy · travel to RIDGELAND, MS · in-kind | $238 |
| Genmab U.S., Inc. Aug 1, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $800 |
| AbbVie Inc. Jul 7, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,175 |
| AbbVie Inc. May 31, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $293 |
| AbbVie Inc. May 30, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $392 |
| Merck Sharp & Dohme LLC May 29, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
| GlaxoSmithKline, LLC. May 7, 2025 | Consulting Fee | $2,000 |
| Eisai Inc. Apr 23, 2025 | Consulting Fee Lenvima · Oncology | $4,075 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee | $400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $353,728 in research payments for these studies, mostly to the institutions running them.
- A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic…
AstraZeneca Pharmaceuticals LP - First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie Inc. · Active, not recruiting · NCT05527184
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.